Compare AstraZeneca plc (AZN) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Silver Trust — how do they compare? AstraZeneca plc trades at $156 (market cap $245.16B), while iShares Silver Trust trades at $58.41. The key difference: AstraZeneca plc pays a 2.02% dividend while iShares Silver Trust pays none, and iShares Silver Trust is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SLV | |
|---|---|---|
Market Cap | $245.16B | — |
Sector | Health | — |
52-Week High | $209.48 | $105.57 |
52-Week Low | $147.06 | $33.89 |
Enterprise Value | $272.43B | — |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.24, down 0.95% on the day, amid bearish technical signals and merger speculation. The company shows strong fundamentals with revenue growth from $44.4B in 2022 to $58.7B in 2025 and net income margin improving to 17.4%. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing selling pressure and legal investigations creating near-term uncertainty.
AZN presents a mixed outlook with strong pharmaceutical fundamentals offset by technical weakness and merger-related volatility. The investment case hinges on continued earnings growth and strategic execution, while risks include integration challenges from potential M&A and ongoing legal scrutiny. Wall Street remains predominantly bullish despite recent price pressure.
SLV (iShares Silver Trust) trades at $59.06, up 0.87% with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides direct exposure to physical silver, benefiting from structural supply deficits and growing industrial demand, particularly from data centers. Recent news highlights silver's rebound after a 50% correction from early 2026 highs, with analysts noting improved risk-reward profiles.
Silver's outlook remains compelling due to constrained supply and robust demand, though the ETF faces volatility risks from Fed policy shifts and dollar strength. Current technical levels show support at $58-59 and resistance at $60-61, with the ADX indicating strong trend momentum despite overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
